My numbers were conservative and P/E ratios are often much higher depending on future revenue / growth (i.e. Amazon currently has a P/E ratio of 91 and has been much higher even just a few years ago).

If cancer trials are positive, I would expect the P/E ratio to be much higher as 10-15 is pretty low and often in the range for staple goods or hardware products.

I expect much higher than $1.40 for CYDY, but I wasn't trying to guess what the share price may be, but merely trying to explain a quick way to calculate these figures. Personally, I conservatively value combo HIV at more than $5/share, based on $3.2B annual sales ($70,000 annual price).